Share This Page
Drugs in ATC Class M04AA
✉ Email this page to a colleague
Drugs in ATC Class: M04AA - Preparations inhibiting uric acid production
| Tradename | Generic Name |
|---|---|
| ALLOPURINOL | allopurinol |
| LOPURIN | allopurinol |
| ZYLOPRIM | allopurinol |
| ALLOPURINOL SODIUM | allopurinol sodium |
| ALOPRIM | allopurinol sodium |
| DUZALLO | allopurinol; lesinurad |
| FEBUXOSTAT | febuxostat |
| >Tradename | >Generic Name |
ATC Class M04AA Preparations inhibiting uric acid production: market dynamics and patent landscape
ATC M04AA market value is driven by chronic hyperuricemia and gout control, with pharmacology split between xanthine oxidase inhibitors (XOIs) and, in certain markets, uricosuric comparators. Patent strategy centers on (1) the small-molecule core chemistry for XO inhibition, (2) formulation and dosing patents for tablets/capsules, and (3) method-of-treatment patents for chronic gout and prophylaxis during urate-lowering therapy. The largest commercial patent estates historically cluster around febuxostat and allopurinol-related filings, while the dominant near-term generic exposure is to branded tablet/capsule products as composition-of-matter and exclusivity layers approach expiry.
ATC M04AA (Preparations inhibiting uric acid production) is largely synonymous with xanthine oxidase inhibitors, principally febuxostat (common in many geographies; ATC M04AA03) and allopurinol (often grouped under M04AA01 across many classification schemes). Market access and revenue allocation are shaped by: (i) guideline-driven chronic use, (ii) physician/payer switching behavior after safety and guideline updates, (iii) formulation tolerability (dose titration, gastrointestinal adverse event mitigation, ease of dosing), and (iv) the availability and pricing of generics/biosimilars-like substitutes (small molecules in this class do not have biosimilar pathways but face ANDA entry).
What patents protect M04AA uric acid production inhibitors?
Core protection is typically composition-of-matter for the active ingredient, supplemented by secondary patents covering polymorphs, particle size, crystalline forms, salts, fixed-dose combinations, and extended-release profiles, plus method-of-use for gout flare prophylaxis during initiation and chronic urate target achievement.
Which drugs are in ATC M04AA and what is driving their sales?
Featured snippet answer: ATC M04AA is dominated by xanthine oxidase inhibitors for lowering serum urate. The sales engine is chronic, long-duration prescribing for gout and hyperuricemia management, with payer and provider behavior influenced by patient comorbidities, guideline preferences, and generic pricing dynamics.
Core therapeutic assets
- Febuxostat (typical M04AA03): widely prescribed where XO inhibition is preferred, especially in patients who do not tolerate allopurinol or where clinicians seek alternative titration.
- Allopurinol (typical M04AA01): long-established standard of care; branded residues persist in some markets, but revenue is increasingly generic-driven.
Market demand profile (commercial dynamics)
- Chronic utilization: urate-lowering therapy is used long-term; the relevant commercial metric is not “new prescriptions” alone, but persistence and dose adherence over years.
- Prophylaxis initiation: guideline-directed prophylaxis during urate lowering creates demand for initiation packs and co-medications, indirectly affecting utilization of M04AA products.
- Safety and switching: safety communications and label changes affect brand-share and accelerate generic substitution in certain segments.
- Pricing pressure: once composition-of-matter protection and exclusivity layers erode, the class shifts toward low-cost generics, compressing branded margins.
Where patent life matters most
- If a branded product retains manufacturing/process or formulation protection, payers can still price-brand above generics while litigation blocks ANDA supply.
- If only method-of-use patents remain, ANDA filers often avoid direct infringement by carving labels to omit protected indications, creating faster erosion of exclusivity.
How many patents cover febuxostat and allopurinol under M04AA, and what are the common claims?
Featured snippet answer: Patent estates for M04AA XO inhibitors typically include composition-of-matter for the active ingredient, plus secondary claim families for crystalline form/polymorph, solid-state properties, particle size distribution, tablets/capsules, and dosing regimens (initiation, titration, and chronic urate targets).
Claim clusters seen across M04AA estates
1) Composition-of-matter (primary)
- Active ingredient synthesis or chemical structure claims
- Variants such as tautomers, hydrates, or salts (where applicable)
2) Solid-state/formulation (secondary)
- Crystalline forms and polymorphs
- Hydrates/solvates
- Particle size and milling processes
- Tablet manufacturing methods that achieve dissolution profiles
3) Method-of-treatment
- Chronic gout urate target achievement
- Flare prophylaxis during initiation
- Dosing schedules tied to lab monitoring
4) Combination and co-therapy
- Fixed-dose combinations are less universal for this class, but combination co-marketing and combination patents can exist for initiation regimens (not always Orange Book-listed for the base ingredient).
Typical geographic coverage
- US: composition-of-matter + formulation + method-of-use often yields Orange Book listing density
- EP/WO: broader chemical coverage is more common; later national phase enforcement may be limited by timing
- CN/IN: filings increase around formulation/process and local salts/polymorphs to sustain market positions
When does patent exclusivity for M04AA urate production inhibitors end, and what timelines matter for generic entry?
Featured snippet answer: Generic entry timing is determined by the later of (i) composition-of-matter patent expiry, (ii) formulation/polymorph expiry, and (iii) any regulatory exclusivity periods tied to branded product approvals or pediatric extensions. Method-of-use patents often become the final gate if ANDA labeling can be designed around them.
US exclusivity framework affecting M04AA
- Orange Book listing drives litigation risk in Hatch-Waxman.
- Generic launch depends on whether an ANDA includes a Paragraph IV challenge and whether courts enjoin launch.
- Pediatric exclusivity (if triggered) can extend effective brand hold by up to 6 months beyond non-pediatric patent expiry.
Practical timing drivers
- Settlement agreements often set “first commercial marketing date,” shifting the launch beyond the earliest legal expiry.
- If a formulation patent blocks, ANDA entrants may seek design-around changes (different polymorph or different excipient strategy), then litigate again.
What is the Orange Book status of febuxostat and allopurinol products in the US?
Featured snippet answer: Orange Book status is product-specific. M04AA brands with still-listed patents tend to show dense listings for formulation and method-of-use, increasing the likelihood of Paragraph IV litigation and delayed generic entry.
How to read Orange Book implications
- Listed patents typically fall into:
- Drug substance (composition-of-matter)
- Drug product (formulation/manufacturing)
- Use codes (method-of-use)
- A high count of product/use codes usually correlates with stronger enforcement posture and more ANDA challenges.
Litigation consequence
- If Orange Book lists a method-of-use patent with a specific use code, ANDA carve-outs can reduce risk, but they can trigger ongoing litigation on labeling, equivalence, or induced infringement.
(No product-level Orange Book listing table is provided here because the requested prompt does not identify specific branded SKUs, NDA/BLA numbers, or assignees for the exact M04AA products to enumerate. Listing-level data must be exact to be actionable.)
What patent litigation affects M04AA generic entry most often?
Featured snippet answer: The most common litigation pattern is Paragraph IV challenges targeting active-ingredient and formulation patents, followed by settlements that either delay launch or allow launch under specific labeling or manufacturing constraints.
Typical litigation pathways
- ANDA filer files Paragraph IV certification against listed US patents
- Brand asserts composition-of-matter and formulation patents
- Courts address claim construction and infringement; settlements may:
- Permit a launch date
- Include non-infringement or covenant-not-to-sue terms
- Require label carve-outs for method-of-use
Design-around focus areas
- Polymorph/crystalline form: ANDA may use a different solid form
- Dissolution profile: formulation changes can avoid certain process claims while maintaining bioequivalence
- Labeling carve-outs: method-of-use patents can be avoided if ANDA labels omit the protected regimen
Enforcement posture indicators
- Multiple listed formulation/process patents often increases the chance of multiple asserted patents per case.
- Broad method-of-use claims (prophylaxis during initiation, chronic urate targets) can drive settlement even if composition-of-matter is close to expiry.
How strong is the patent estate for urate production inhibitors versus competitors?
Featured snippet answer: Patent strength in M04AA is strongest when composition-of-matter plus formulation solid-state patents overlap with ongoing Orange Book listings. It weakens when method-of-use is the dominant remaining layer and can be carved out in ANDA labeling.
Competitive estate structure
- Composition-of-matter dominance: longer legal runway, higher litigation intensity, greater barrier to full substitution.
- Formulation dominance: still enforceable in ANDA under product patent regimes, but design-around via alternate solids or manufacturing process may reduce infringement.
- Method-of-use dominance: easier to design around in labeling; litigation may shift to inducement, off-label promotion risks, and Hatch-Waxman “use-based” certifications.
Market outcome
- Strong composition/formulation estates delay generic pricing and sustain higher reimbursement for branded M04AA products.
- Weaker method-of-use-only estates accelerate generic penetration and compress revenue for the originator unless it can differentiate on adherence, safety profile, or contracting.
(A side-by-side comparative patent matrix cannot be produced without specific product identifiers and jurisdictional patent lists.)
What generic entry risks exist for manufacturers seeking ANDA approval in M04AA?
Featured snippet answer: The main risks are (i) injunctions due to asserted Orange Book formulation patents, (ii) settlement-driven delayed launches, and (iii) labeling carve-out disputes for method-of-use claims.
Commercial risk factors for ANDA entrants
- Multiple listed patents for a single NDA can require sequential litigation and multiple settlement touchpoints.
- Polymorph/formulation switching may be nontrivial for bioequivalence and manufacturing validation.
- Labeling certification strategy can influence whether brand claims induced infringement, especially if clinical practice patterns make carved indications hard to avoid.
Manufacturing/IP barriers
- Patent-protected processes for particle size, milling, granulation, and tablet compression can block straightforward scale-up.
- Solid-state IP around specific crystalline forms forces entrants to validate the alternative solid form’s stability and performance.
How do formulation patents and solid-state IP affect M04AA pricing and supply?
Featured snippet answer: Solid-state and formulation patents can delay generic substitution even after chemical expiry by blocking commercially interchangeable tablet/capsule manufacture using protected solids or protected process steps.
Common formulation levers
- Controlled dissolution for consistent urate-lowering effect
- Grain size and flow characteristics for manufacturing yield
- Moisture stability and shelf-life improvements
Pricing impact
- If brand retains enforceable product patents, payers and providers face fewer low-cost alternatives, sustaining higher net pricing longer.
What method-of-use patents can block or shape M04AA ANDA labeling?
Featured snippet answer: Method-of-use patents typically target gout initiation regimens and chronic management targets. ANDA entrants can certify to omit protected uses, but enforcement can move to labeling, induced infringement, and real-world prescribing patterns.
Typical method-of-use categories
- Flare prophylaxis during initiation of urate-lowering therapy
- Chronic maintenance dosing to reach serum urate targets
- Monitoring-based titration regimens
Litigation shape
- Courts may focus on whether label instructions and marketing imply the protected regimen
- Settlements often standardize labeling language to avoid direct infringement.
Which companies are challenging patents or defending M04AA brands?
Featured snippet answer: Company identity depends on the specific M04AA brand SKU and jurisdiction. In Hatch-Waxman, challenges typically originate from established generic manufacturers and settlement negotiations frequently involve brand originators and first-wave ANDA filers.
(A named competitor list is not included because the prompt does not specify the exact M04AA product(s), NDA numbers, or patent assignees needed to reliably enumerate parties.)
What settlement agreements typically do for M04AA exclusivity?
Featured snippet answer: Settlements commonly trade off litigation cost for predictable launch dates, convert disputed claims into a scheduled entry window, and require label carve-outs tied to method-of-use patents.
Settlement mechanics that matter commercially
- Scheduled entry dates tied to the latest relevant expiry or “end of stay”
- Covenants not to sue conditioned on:
- Labeling language
- Product composition/formulation constraints
- Manufacturing conditions
Net effect
- Even when legal expiry would allow earlier entry, settlements can extend brand revenue and delay commoditization.
How does FDA regulatory status interact with patent strategy in ATC M04AA?
Featured snippet answer: Patent strategy in M04AA is intertwined with FDA labeling and approval pathways. ANDA entrants manage risk through Paragraph IV certifications and label design to reduce infringement under listed patents.
Key FDA pathway interactions
- Brand NDA defines:
- Indications and dosing language (impacting method-of-use risk)
- Strengths and dosage forms (impacting product patent risk)
- Generic ANDA:
- Must show bioequivalence
- Must certify to each Orange Book patent and choose the correct carve-out strategy for method-of-use
- Can trigger § 505(j)(2)(A) notice obligations and litigation stays
Key Takeaways
- ATC M04AA is a small-molecule, xanthine oxidase inhibitor market where patent durability largely depends on composition-of-matter plus solid-state/formulation and method-of-use layers.
- Generic entry timing in the US is governed by Orange Book-listed patents, Paragraph IV litigation, and settlement-driven launch dates.
- The highest litigation and commercial risk for ANDA filers is typically formulation/solid-state protection and label-based method-of-use disputes.
- Market dynamics favor incumbents where product patents remain enforceable and penalize them once only design-aroundable method-of-use claims remain.
FAQs
- What is the fastest generic entry path for xanthine oxidase inhibitors when remaining patents are method-of-use only?
- How do polymorph and crystalline form patents typically get challenged for ANDA approvals in M04AA?
- What labeling carve-out language most often determines whether an ANDA avoids method-of-use infringement in gout initiation prophylaxis?
- Which factors most influence payer switching from branded febuxostat to generic allopurinol or vice versa?
- How do formulation patents on tablet manufacturing processes affect bioequivalence strategies for M04AA generics?
References
- European Medicines Agency. (n.d.). ATC classification and therapeutic group information.
- US Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- FDA. (n.d.). ANDA and Paragraph IV certification framework under Hatch-Waxman (Section 505(j)).
More… ↓
